Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14549996 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL14480293 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL4205894 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL31684351 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL7000145 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL5679362 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL18631695 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL3028218 | 1.00 | FFAR1 (0.49) | FFAR1HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL4133997 | 0.85 | HTR2A (0.51) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL4133995 | 0.85 | HTR2A (0.51) | HTR2AHTR2CHTR2BALDH1A1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3372582-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2018-09-12 | — | — | EP | disclosed |
| US-20180250277-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2018-09-06 | — | — | US | disclosed |
| EP-2729447-B1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H LUNDBECK AS (DK) | 2018-05-30 | — | — | EP | disclosed |
| US-9889122-B2 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2018-02-13 | — | — | US | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170079967-A1 | New Positive Allosteric Modulators or Nicotinic Acetylcholine Receptor | H. LUNDBECK A/S (DK) | 2017-03-23 | — | — | US | disclosed |
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8598213-B2 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-12-03 | — | — | US | disclosed |
| WO-2013007621-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2013-01-17 | — | — | WO | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-6251910-B1 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists | ASTRAZENECA UK LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
| US-6172091-B1 | METABOLIC CALCIUM IMBALANCE AND OSTEOPOROSIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000021910-A2 | 1,2-DISUBSTITUTED CYCLOPROPANES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250277-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | CHRNG, CHRNA7, CHRNA2 | FFAR1 318/4885HTR2A 436/4885HTR2C 611/4885 |
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNK17, KCNN3, KCNA7 | FFAR1 2816/4885HTR2A 910/4885HTR2C 564/4885 |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | FFAR1 303/4885HTR2A 399/4885HTR2C 534/4885 |
| US-20170079967-A1 | New Positive Allosteric Modulators or Nicotinic Acetylcholine Receptor | CHRNG, CHRNA7, CHRNA1 | FFAR1 285/4885HTR2A 391/4885HTR2C 533/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | FFAR1 3173/4885HTR2A 4240/4885HTR2C 4299/4885 |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | FFAR1 3173/4885HTR2A 4240/4885HTR2C 4299/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | FFAR1 43/4885HTR2A 2/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.